Literature DB >> 10628529

NMDA receptor hypofunction model of schizophrenia.

J W Olney1, J W Newcomer, N B Farber.   

Abstract

Several decades of research attempting to explain schizophrenia in terms of the dopamine hyperactivity hypothesis have produced disappointing results. A new hypothesis focusing on hypofunction of the NMDA glutamate transmitter system is emerging as a potentially more promising concept. In this article, we present a version of the NMDA receptor hypofunction hypothesis that has evolved from our recent studies pertaining to the neurotoxic and psychotomimetic effects of PCP and related NMDA antagonist drugs. In this article, we examine this hypothesis in terms of its strengths and weaknesses, its therapeutic implications and ways in which it can be further tested.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10628529     DOI: 10.1016/s0022-3956(99)00029-1

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  294 in total

1.  A default mode of brain function.

Authors:  M E Raichle; A M MacLeod; A Z Snyder; W J Powers; D A Gusnard; G L Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

Review 2.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

Review 3.  The discovery of susceptibility genes for mental disorders.

Authors:  C Robert Cloninger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

Review 4.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

5.  3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  Ruth Condray; George G Dougherty; Matcheri S Keshavan; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk; Jeffrey K Yao
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 5.176

Review 6.  General anesthesia and altered states of arousal: a systems neuroscience analysis.

Authors:  Emery N Brown; Patrick L Purdon; Christa J Van Dort
Journal:  Annu Rev Neurosci       Date:  2011       Impact factor: 12.449

Review 7.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

8.  Ab initio studies of receptor interactions with AMPA ((S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid) and kainic acid (2S-(2 alpha, 3 beta, 4 beta))-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid.

Authors:  Elise Champeil; Gloria Proni; Danielle Sapse
Journal:  J Mol Model       Date:  2009-02-21       Impact factor: 1.810

Review 9.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

10.  NR1 knockdown reveals CA1 injury during a developmental period of high seizure susceptibility despite reduced seizure activity.

Authors:  J Kaur; R Keesey; B Magrys; H Liu; L K Friedman
Journal:  Neuromolecular Med       Date:  2007-08-14       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.